Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06257043Recruiting
Real-world study of aortic valve replacement
This trial is studying how well a new type of heart valve works in real-life patients with aortic valve disease. It will help doctors understand if this valve is safe and effective for people who need a procedure called TAVR (transcatheter aortic valve replacement).
Xi'an, ShaanxiAges 18 years+ - NCT06257355RecruitingPhase 1
Testing a new eye drop for corneal scars
This trial tests a new eye drop to see if it can safely and effectively reduce corneal scars. It is for people who have a recent corneal injury (within the last month) that resulted in a scar that affects their vision.
Loma Linda, CaliforniaAges 18–80 - NCT06260007RecruitingPhase 4
Study of a natural supplement for men with low sperm count
This trial tests if a supplement made from Tribulus Terrestris (a plant) can help men with low sperm count (oligospermia) improve their fertility. It may be an option for men who are considering hormone treatments.
Valinhos, São PauloAges 25–60 - NCT06261554Recruiting
Low-dose sesame oral immunotherapy for children
This study tests if a very low daily dose of sesame protein (given as a powder under the tongue) can help children with sesame allergy become less sensitive to sesame. The goal is to reduce the risk of severe allergic reactions from accidental exposure.
Warsaw, Masovian VoivodeshipAges 3–17 - NCT06263959RecruitingPhase 2
Testing a new hepatitis B pill (GST-HG131) for chronic HBV
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
BeijingAges 35–65 - NCT06264531RecruitingPhase 2/Phase 3
Bevacizumab for adults with symptomatic, untreatable brain AVMs
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
Paris, Île-de-France RegionAges 18 years+ - NCT06266832RecruitingPhase 2
Short-course radiation with immunotherapy and chemo for rectal cancer
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
Hangzhou, ZhejiangAges 18 years+ - NCT06275516Recruiting
Virtual Reality with Sights, Sounds, and Touch for Stroke Recovery
This study tests whether a special virtual reality program that uses sights, sounds, and touch can help people who have had a stroke move their leg better. You might qualify if you had a first stroke, have trouble moving your leg, and can walk a little bit with help.
Chongqing, Chongqing MunicipalityAges 18–85 - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT06278454RecruitingPhase 1
Radioactive injection for advanced pancreatic cancer
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
Zhengzhou, HenanAges 18–80 - NCT06279741RecruitingPhase 1/Phase 2
Cell therapy to prevent lung disease in very premature babies
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
BrusselsAges Up to 1 week - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+ - NCT06282965RecruitingPhase 1/Phase 2
Angiotensin (1-7) for moderate to severe brain injury
This study tests a drug called Angiotensin (1-7) to see if it helps people recover from moderate to severe traumatic brain injury. It may reduce damage and improve healing when given shortly after the injury.
Tucson, ArizonaAges 18 years+ - NCT06284057Recruiting
Culotte stent technique study for Y-shaped heart blockages
This trial studies two different ways of placing stents in Y-shaped blockages in the heart's arteries. It aims to find which technique works best for people who need two stents in that area.
Legnica, Lower Silesian VoivodeshipAges 18 years+ - NCT06284876RecruitingPhase 3
Testing Ilaprazole for Preventing NSAID-Related Stomach Ulcers
This study tests a new medicine called Ilaprazole 10 mg to see if it can prevent stomach ulcers caused by NSAIDs (pain relievers like ibuprofen). If you take NSAIDs regularly and have a higher risk of ulcers, this trial may help protect your stomach.
SeoulAges 19 years+ - NCT06286150Recruiting
Testing a new single-port robot for lung surgery
This trial studies a new surgical robot that uses only one small opening in the chest to remove a lung segment or lobe. It aims to see if the robot is safe and effective for patients who need this type of surgery.
Guangzhou, GuangdongAges 18–75 - NCT06288165Recruiting
Sinus reducer trial for persistent chest pain
This study tests a device called the sinus reducer for people with long-lasting chest pain that hasn't improved with medication or other procedures. It may help if you have limited options for treatment.
Lubin, Lower Silesian VoivodeshipAges 18 years+ - NCT06291025Recruiting
Testing a simpler treatment for immune-mediated TTP
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
AmiensAges 18 years+ - NCT06290661Recruiting
Nerve stimulation for shingles-related nerve pain
This study tests a treatment called peripheral nerve stimulation (using a small device to send mild electrical pulses) for people with nerve pain after shingles. It's designed for those whose pain is not well managed by usual treatments.
Wuhan, HubeiAges 18 years+ - NCT06292650RecruitingEarly Phase 1
Gene therapy ZM-02 for advanced retinitis pigmentosa
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
Beijing, Beijing MunicipalityAges 18–65 - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT06295614Recruiting
ARC-IM therapy for walking problems in Parkinson's
This study tests a new therapy called ARC-IM to help with walking issues like freezing or balance problems in people with Parkinson's. It aims to see if the therapy is safe and can improve movement.
Lausanne, Canton of VaudAges 18 years+ - NCT06296121RecruitingPhase 3
BCD-264 vs Darzalex for relapsed multiple myeloma
This trial tests a new drug, BCD-264, compared to Darzalex (daratumumab) alone for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if BCD-264 works better than Darzalex in controlling the cancer.
ChelyabinskAges 18 years+ - NCT06296212RecruitingPhase 3
Testing TAD injection to protect the heart during pneumonia
This trial tests if a medicine called TAD® (glutathione injection) can help prevent heart injury in people hospitalized with pneumonia. It is for patients who also have heart risks or conditions, and takes place in the hospital.
Pisa, PIAges 18–80
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.